Claims
- 1. A method of treating vasculogenic sexual dysfunction in a female mammal in need of such treatment which comprises administering to said female a therapeutically effective amount of a compound which acts upon a mid-brain pathway to increase blood flow in the ilio-hypogastric-pudendal arterial bed.
- 2. A method according to claim 1 wherein said compound acts upon a dopaminergic mid-brain pathway to increase blood flow in the ilio-hypogastric-pudendal arterial bed.
- 3. A method according to claim 1 wherein said compound acts upon a serotonergic mid-brain pathway to increase blood flow in the ilio-hypogastric-pudendal arterial bed.
- 4. A method according to claim 1 wherein said compound acts upon an oxytocinergic mid-brain pathway to increase blood flow in the ilio-hypogastric-pudendal arterial bed.
- 5. A method according to claim 1 wherein said compound acts upon a nitroxidergic mid-brain pathway to increase blood flow in the ilio-hypogastric-pudendal arterial bed.
- 6. A method according to claim 2 wherein said compound acting upon a mid-brain dopaminergic pathway is selected from the group consisting of apomorphine, bromocriptine, lisuride, methergoline, pergolide, pribidil and quinapril or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 7. A method according to claim 3 wherein said compound acting upon a mid-brain serotonergic pathway is selected from the group consisting of 1-(2,5-dimethoxy-4-iodophenyl)-1-aminopropane, 5-methoxytryptamine, α-methyl-5-hydroxytryptamine, 2-methyl-5-hydroxytryptamine, N-acetyl-5-hydroxytryptamine, buspirone, and sumatriptin or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 8. A method according to claim 4 wherein said compound acting upon a mid-brain oxytocinergic pathway is selected from the group consisting of isotocin, carbetocin, Lys-conopressin, deaminooxytocin, mesotocin, antocin, glumitocin, aspargitocin, valitocin, asvatocin, phasvatocin, and seritocin or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 9. A method of treating vasculogenic sexual dysfunction in a female in need of such treatment which comprises administering to a patient in need of such treatment a therapeutically effective amount of apomorphine of a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 10. The method of claim 9 wherein said apomorphine is administered in an amount sufficient to produce an effective vasocongestive arousal in said female, but insufficient to induce nausea.
- 11. The method of claim 10 wherein said apomorphine is administered in an amount between about 25 micrograms/kg of body weight and about 60 micrograms/kg of body weight.
- 12. The method of claim 9 wherein said apomorphine is administered in an amount sufficient to establish plasma concentration levels of apomorphine ranging between about 0.3 to about 5.5 nanograms/mL.
- 13. The method of claim 12 wherein said plasma levels of apomorphine range between about 0.3 and about 4 nanograms/mL.
- 14. The method of claim 13 wherein said plasma levels of apomorphine range between about 1 and about 2 nanograms/mL.
- 15. A method of inducing effective vasocon-strictive arousal in a female in need of such treatment comprising administering a therapeutically effective amount of apomorphine or a pharmaceutically effective salt, ester, or pro-drug thereof.
- 16. The method of claim 15 wherein said apomorphine is administered in the interval between about 120 minuites and 2 minutes prior to coitus.
- 17. The method of claim 16 wherein said apomorphine is administered over a period of time ranging between about two to about ten minutes.
- 18. The method of claim 17 wherein said apomorphine is administered sublingually.
- 19. A method of treating vaginal engorgement insufficiency in a female in need of such treatment comprising administering a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt, ester or pro-drug thereof.
- 20. The method of claim 19 wherein said apomorphine is administered in an amount between about 25 micrograms/kg of body weight and about 60 micrograms/kg of body weight.
- 21. The method of claim 20 wherein said apomorphine is administered in an amount sufficient to establish plasma concentration levels of apomorphine ranging between about 0.3 to about 5.5 nanograms/mL.
- 22. The method of claim 21 wherein said plasma levels of apomorphine range between about 0.3 and about 4 nanograms/mL.
- 23. The method of claim 22 wherein said plasma levels of apomorphine range between about 1 and about 2 nanograms/mL.
- 24. The method of claim 19 wherein said apomorphine is administered in the interval between about 120 minuites and 2 minutes prior to coitus.
- 25. The method of claim 24 wherein said apomorphine is administered over a period of time ranging between about two to about ten minutes.
- 26. The method of claim 19 wherein said apomorphine is administered sublingually.
- 27. A method of treating clitoral erectile insufficiency in a female in need of such treatment comprising administering a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt, ester or pro-drug thereof.
- 28. The method of claim 27 wherein said apomorphine is administered in an amount between about 25 micrograms/kg of body weight and about 60 micrograms/kg of body weight.
- 29. The method of claim 27 wherein said apomorphine is administered in an amount sufficient to establish plasma concentration levels of apomorphine ranging between about 0.3 to about 5.5 nanograms/mL.
- 30. The method of claim 29 wherein said plasma levels of apomorphine range between about 0.3 and about 4 nanograms/mL.
- 31. The method of claim 30 wherein said plasma levels of apomorphine range between about 1 and about 2 nanograms/mL.
- 32. The method of claim 27 wherein said apomorphine is administered in the interval between about 120 minutes and 2 minutes prior to coitus.
- 33. The method of claim 32 wherein said apomorphine is administered over a period of time ranging between about two to about ten minutes.
- 34. The method of claim 32 wherein said apomorphine is administered sublingually.
- 35. A method of combating vaginal pain comprising administering to a female in need of such treatment a compound which acts upon mid-brain neural pathways to stimulate peripheral pelvic non-adrenergic non-cholinergic (NANC) nerve cell release of nitric oxide (NO).
- 36. A method according to claim 35 wherein said compound acts upon a dopaminergic mid-brain pathway to stimulate peripheral pelvic NANC cell release of nitric oxide (NO).
- 37. A method according to claim 35 wherein said compound acts upon a serotonergic mid-brain pathway to stimulate peripheral pelvic NANC nerve cell release of nitric oxide (NO).
- 38. A method according to claim 35 wherein said compound acts upon an oxytocinergic mid-brain pathway to stimulate peripheral pelvic NANC nerve cell release of nitric oxide (NO).
- 39. A method according to claim 35 wherein said compound acts upon a nitroxidergic mid-brain pathway to stimulate peripheral pelvic NANC nerve cell release of nitric oxide (NO).
- 40. A method according to claim 36 wherein said compound acting upon a mid-brain dopaminergic pathway is selected from the group consisting of apomorphine, bromocriptine, lisuride, methergoline, pergolide, pribidil and quinapril or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 41. A method according to claim 37 wherein said compound acting upon a mid-brain serotonergic pathway is selected from the group consisting of 1-(2,5-dimethoxy-4-iodophenyl)-1-aminopropane, 5-methoxytryptamine, α-methyl-5-hydroxytryptamine, 2-methyl-5-hydroxytryptamine, N-acetyl-5-hydroxytryptamine, buspirone, and sumatriptin or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 42. A method according to claim 39 wherein said compound acting upon a mid-brain oxytocinergic pathway is selected from the group consisting of isotocin, carbetocin, Lys-conopressin, deaminooxytocin, mesotocin, antocin, glumitocin, aspargitocin, valitocin, asvatocin, phasvatocin, and seritocin or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 43. A method of treating vaginal pain in a female in need of such treatment which comprises administering to a patient in need of such treatment a therapeutically effective amount of apomorphine of a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 44. The method of claim 43 wherein said apomorphine is administered in an amount between about 25 micrograms/kg of body weight and about 60 micrograms/kg of body weight.
- 45. The method of claim 42 wherein said apomorphine is administered in an amount sufficient to establish plasma concentration levels of apomorphine ranging between about 0.3 to about 5.5 nanograms/mL.
- 46. The method of claim 45 wherein said plasma levels of apomorphine range between about 0.3 and about 4 nanograms/mL.
- 47. The method of claim 46 wherein said plasma levels of apomorphine range between about 1 and about 2 nanograms/mL.
- 48. The method of claim 35 wherein said apomorphine is administered sublingually.
- 49. A method of treating dyspareunia in a female in need of such treatment comprising administering a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 50. The method of claim 49 wherein said apomorphine is administered in an amount between about 25 micrograms/kg of body weight and about 60 micrograms/kg of body weight.
- 51. The method of claim 49 wherein said apomorphine is administered in an amount sufficient to establish plasma concentration levels of apomorphine ranging between about 0.3 to about 5.5 nanograms/mL.
- 52. The method of claim 51 wherein said plasma levels of apomorphine range between about 0.3 and about 4 nanograms/mL.
- 53. The method of claim 52 wherein said plasma levels of apomorphine range between about 1 and about 2 nanograms/mL.
- 54. The method of claim 49 wherein said apomorphine is administered in the interval between about 120 minutes and 2 minutes prior to coitus.
- 55. The method of claim 49 wherein said apomorphine is administered over a period of time ranging between about two to about ten minutes.
- 56. The method of claim 41 wherein said apomorphine is administered sublingually.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of co-pending application, Ser. No. 08/546,498 filed Oct. 20, 1995, now U.S. Pat. No. 5,770,606 which, in turn, is a continuation-in-part of application Ser. No. 08/231,250 filed on Apr. 22, 1994, now abandoned.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09102987 |
Jun 1998 |
US |
Child |
10136387 |
May 2002 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
08546498 |
Oct 1995 |
US |
Child |
09102987 |
Jun 1998 |
US |
Parent |
08231250 |
Apr 1994 |
US |
Child |
08546498 |
Oct 1995 |
US |